Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas, MD, National Institute of Pediatrics, Mexico City, Mexico, discusses a study conducted in Mexico investigating the efficacy of blinatumomab to achieve remission followed by consolidation with haploidentical stem cell transplantation (haploSCT) and cyclophosphamide in pediatric acute lymphoblastic leukemia (ALL). The regimen achieved an overall survival (OS) between 70 and 75%, compared to 0% for those who did not receive haploSCT. These findings support the use of blinatumomab plus haploSCT to achieve prolonged remission in patients with ALL who are at a high risk of relapse. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.